Impact of metabolic syndrome on coronary patency after thrombolytic therapy for acute myocardial infarction

Coronary Artery Disease

Volumn 20, Issue 6, 2009, Pages 387-391

  Saatci Yasar, Ayse ^a   Bilen, Emine ^a   Bilge, Mehmet ^a   Arslantas, Ugur ^a   Karakas, Fatih ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Metabolic syndrome; Myocardial infarction; Thrombolysis in myocardial infarction flow grade

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; ENOXAPARIN; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; ARTERY DIAMETER; ARTICLE; BLOOD CLOT LYSIS; CORONARY ARTERY; FEMALE; FIBRINOLYTIC THERAPY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION; SURVIVAL TIME;

AGED; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 69349098620     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328330d557     Document Type: Article

References (28)

1. Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159:1104-1109. (Pubitemid 29230863)
2. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999; 83:25F-29F.
3. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285:2486-2497.
4. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-689. (Pubitemid 32893993)
5. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, et al. 4S Group and the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93:136-141.
6. Turhan H, Yasar AS, Basar N, Bicer A, Erbay AR, Yetkin E. High prevalence of metabolic syndrome among young women with premature coronary artery disease. Coronary Artery Dis 2005; 16:37-40. (Pubitemid 40279596)
7. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110:1245-1250. (Pubitemid 39202340)
8. Zeller M, Steg PG, Ravisy J, Laurent Y, Janin-Manifact L, L'Huillier I, et al. Observatiore des Infarctus de Cote-d'Or Survey working Group. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med 2005; 165:1192-1198.
9. Takeno M, Yasuda S, Otsuka Y, Morii I, Kawamura A, Yano K, et al. Impact of metabolic syndrome on the long-term survival of patients with acute myocardial infarction. Circ J 2008; 72:415-419.
10. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Circulation 1993; 87:1829-1839.
11. Anderson JL. Overview of patency as an end point of thrombolytic therapy. Am J Cardiol 1991; 67:11E-16E.
12. Califf RM, Topol EJ, Gersh BJ. From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. J Am Coll Cardiol 1989; 14:1382-1388. (Pubitemid 19268696)
13. Gomez MA, Karagounis LA, Allen A, Anderson JL. Effect of cigarette smoking on coronary patency after thrombolytic therapy for myocardial infarction. Am J Cardiol 1993; 72:373-378. (Pubitemid 23238417)
14. Lundergan CF, Reiner JS, McCarthy WF, Coyne KS, Califf RM, Ross AM. Clinical predictors of early infarct-related artery patency follwing thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. J Am Coll Cardiol 1998; 32:641-647.
15. TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: phase I findings. N Engl J Med 1985; 312:932-936. (Pubitemid 15105692)
16. Gibson CM, Murphy SA, Rizzo MJ, Ryan KA, Marble SJ, McCabe CH, et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Circulation 1999; 99:1945-1950.
17. Antman EM, Morrow DA, McCabe CH, Jiang F, White HD, Fox KA, et al. ExTRACT-TIMI25 Investigators. Enoxaparin versus unfractionated heparin as antitrombin in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis In Myocardial Infarction study 25 (ExTRACT -TIMI 25). Am Heart J 2005; 149:217-226. (Pubitemid 40348526)
18. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989; 2:358-367.
19. Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, et al. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 2007; 61:548-553. (Pubitemid 46605227)
20. Levantesi G, Macchia A, Marfisi R, Franzosi MG, Maggioni AP, Nicolosi GL, et al. GISSI-Prevenzione Investigators. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 2005; 46:277-283.
21. Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, et al. Study of health assessment and risk in ethnic groups. Study of Health assessment and Risk evaluation in aboriginal peoples investigators. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003; 108:420-425.
22. Almer LO, Ohlin H. Elevated levels of the rapid inhibitor of plasminogen activator (tPAI) in acute myocardial infarction. Thromb Res 1987; 47:335-339. (Pubitemid 17106258)
23. Potter van Loon BJ, Rijken DC, Brommer EJ, van der Maas AP. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex vivo lysibility. Thromb Haemost 1992; 67:101-105.
24. Sane DC, Stump DC, Topol EJ, Sigmon KN, Kereiakes DJ, George BS, et al. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemost 1991; 65:275-279.
25. Barbash GI, Hod H, Roth A, Miller HI, Rath S, Zahav YH, et al. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1989; 64:1231-1235. (Pubitemid 20000067)
26. Serebruany VL, Malinin A, Ong S, Atar D. Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. J Thromb Thrombolysis 2008; 25:207-213. (Pubitemid 351595984)
27. Arenillas JF, Ispierto L, Millan M, Escudero D, Perez de la Ossa N, Dorado N, et al. Metabolic syndrome and resistance to IV thrombolysis in middle cerebral artery ischemic stroke. Neurology 2008; 71:190-196.
28. Clavijo LC, Pinto TL, Kuchulakanti RT, Chu WW, Satler LF, Kent KM, et al. Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications. Cardiovasc Revasc Med 2006; 7:7-11.